QUICK ANSWER · AEO / GEO
An experimental growth-hormone secretagogue with early human research and no established broad therapeutic approval.
ENTITY FACTS
What should readers identify first?
What remains unknown?
English translation is not yet verified for 6 excerpt(s). This is a language gap, not an absence of risks or uncertainty.
Read original excerpts (Thai / mixed language)
- ประสิทธิผลและความปลอดภัยระยะยาวในคน
- ผลต่อ glucose, insulin, cortisol และ pituitary regulation เมื่อได้รับซ้ำ
- ความหมายทางคลินิกของ acute LVEF change และ CD36-related mechanisms
- ประโยชน์ต่อ muscle, fat, physical function, recovery หรือ aging outcomes
- สถานะ marketing authorisation ปัจจุบันในไทย สหรัฐฯ EU และ UK หากไม่มี product record โดยตรง
- identity, potency, sterility และ impurities ของ online หรือ compounded products
What limits these conclusions?
English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.
Read original excerpts (Thai / mixed language)
- งานมนุษย์ส่วนใหญ่เก่า ขนาดเล็ก ระยะสั้น และวัด hormone response มากกว่า patient-important outcomes งาน cardiovascular ในคนมีเพียงผู้เข้าร่วมจำนวนน้อยและประเมินผลเฉียบพลัน ส่วนคำกล่าวอ้าง cardioprotection จำนวนมากมาจากเซลล์หรือสัตว์ จึงไม่ควรขยายเป็นการรักษาในมนุษย์
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://precision.fda.gov/uniisearch/srs/unii/09qf37c617
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025
- https://pubmed.ncbi.nlm.nih.gov/7957536/
- https://pubmed.ncbi.nlm.nih.gov/7673411/
- https://pubmed.ncbi.nlm.nih.gov/10342360/
- https://pubmed.ncbi.nlm.nih.gov/9253314/
- https://pubmed.ncbi.nlm.nih.gov/12379504/
- https://pubmed.ncbi.nlm.nih.gov/24747279/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://www.ema.europa.eu/en/medicines/download-medicine-data
- https://products.mhra.gov.uk/
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
FAQ · ANSWER ENGINE
Frequently asked questions
What is Hexarelin / Examorelin?
Hexarelin / Examorelin is described pharmacologically as Synthetic growth hormone-releasing hexapeptide / ghrelin-receptor agonist. An experimental growth-hormone secretagogue with early human research and no established broad therapeutic approval.
Does Hexarelin / Examorelin have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Hexarelin / Examorelin approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.